Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether ABSORB bioresorbable vascular scaffold is non-inferior to XIENCE everolimus-eluting cobalt-chromium stent with respect to target-lesion failure (TLF) at 1 year.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02831205
Study type Interventional
Source Asan Medical Center
Contact
Status Terminated
Phase Phase 4
Start date July 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT00767663 - Persantin Preceding Elective PCI Phase 4
Withdrawn NCT02784418 - The SHINE-CTO Trial N/A
Active, not recruiting NCT02042300 - XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
Recruiting NCT03209414 - Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Active, not recruiting NCT02939872 - Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events Phase 4
Recruiting NCT05972070 - Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
Recruiting NCT02797561 - Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions
Not yet recruiting NCT04455568 - Establish a Telecare Model of Acute Coronary Syndrome Patient With Heart Stent Implantation by a Non-invasive Wearable Device and Artificial Intelligence Cloud to Reducing Medical Adverse Events.
Recruiting NCT01186133 - Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
Recruiting NCT02497014 - The European Bifurcation Club Left Main Study N/A
Terminated NCT02831218 - Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation N/A